STAAR Surgical Company (STAA)

Market Cap	1.30B
Revenue (ttm)	341.22M
Net Income (ttm)	21.78M
Shares Out	49.26M
EPS (ttm)	0.44
PE Ratio	59.83
Forward PE	37.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	479,861
Open	26.01
Previous Close	26.14
Day's Range	25.89 - 26.87
52-Week Range	25.89 - 52.68
Beta	0.62
Analysts	Buy
Price Target	43.33 (+64.63%)
Earnings Date	Oct 30, 2024

About STAA

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are prima...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 1,057
• Stock Exchange: NASDAQ
• Ticker Symbol: STAA
• Website: https://www.staar.com

Financial Performance

In 2023, STAAR Surgical Company's revenue was $322.42 million, an increase of 13.37% compared to the previous year's $284.39 million. Earnings were $21.35 million, a decrease of -46.18%.

Analyst Forecast

According to 7 analysts, the average rating for STAA stock is "Buy." The 12-month stock price forecast is $43.33, which is an increase of 64.63% from the latest price.

Price Target

$43.33

(64.63% upside)

Analyst Consensus: Buy